市場調查報告書

多發性骨髓瘤:流行病學的預測(到2030年)

Multiple Myeloma - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 955317
出版日期 內容資訊 英文 200 Pages
商品交期: 最快1-2個工作天內
價格
多發性骨髓瘤:流行病學的預測(到2030年) Multiple Myeloma - Epidemiology Forecast to 2030
出版日期: 2020年08月01日內容資訊: 英文 200 Pages
簡介

全球主要8個國家 (8MM) 的多發性骨髓瘤 (MM)的發病數量,2017年達到了總合85,971件。其中美國國內的發病數量是30,271件,德國是7,337件,日本是7,504件。中國的發病數量2017年達到19,536件,今後 (到2030年) 也可能進一步增加。

本報告提供全球主要8個國家 - 美國、歐洲主要5個國家(EU5:法國、德國、義大利、西班牙、英國)、日本 - 的多發性骨髓瘤 (MM)的流行病學趨勢與今後的預測分析著。

目錄

第1章 主要考察

第2章 多發性骨髓瘤 (MM):摘要整理

第3章 專家 (KOL)的見解

第4章 多發性骨髓瘤(MM)的SWOT分析

第5章 多發性骨髓瘤:市場概要

第6章 疾病的背景和概要:多發性骨髓瘤(MM)

  • 簡介
  • 多發性骨髓瘤的特徵
    • 低血球數
    • 骨和鈣的問題
    • 感染疾病
    • 腎臟的問題
  • 多發性骨髓瘤的病因
  • 多發性骨髓瘤的危險因素
  • 徵兆與症狀
    • 骨的問題
    • 血中鈣濃度高
    • 神經系統的症狀
    • 腎臟的問題
  • 多發性骨髓瘤的病因
    • 多發性骨髓瘤的進展的分子機制
    • 多發性骨髓瘤與其癌症前期病變性前驅細胞的分子病理
  • 多發性骨髓瘤的病理生理學
  • 患者相關的危險因素
  • 多發性骨髓瘤的生物標記
    • 生物標記的血清M蛋白質和輕鏈
    • 潛在的蛋白質體學生物標記
    • 多發性骨髓瘤的細胞遺傳學的生物標記

第7章 多發性骨髓瘤的診斷

  • 檢驗室檢驗
  • 切片檢查
  • 影像檢查
  • 多發性骨髓瘤的分期

第8章 流行病學和患者人口

  • 在流行病學方面的主要的要點
  • 假設和根據:主要8個國家(8MM)的場合
  • 流行病學方案:主要8個國家(8MM)的場合
    • 多發性骨髓瘤的總發病數量
    • 多發性骨髓瘤的患病者總數
    • 多發性骨髓瘤的患病人數:男女
    • 多發性骨髓瘤的已受診患病人數:各年齡
    • 多發性骨髓瘤的病例數:各治療的選項

第9章 美國的流行病學的趨勢

  • 多發性骨髓瘤的總發病數量
  • 多發性骨髓瘤的患病者總數
  • 多發性骨髓瘤的患病人數:男女
  • 多發性骨髓瘤的已受診患病人數:各年齡
  • 多發性骨髓瘤的病例數:各治療的選項

第10章 (EU5)的流行病學的趨勢歐洲主要5個國家

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國

第11章 日本的流行病學的趨勢

第12章 中國的流行病學的趨勢

第13章 附錄

第14章 DelveInsight的服務內容

第15章 免責聲明

第16章 關於DelveInsight

目錄
Product Code: DIEI0321

DelveInsight's 'Multiple Myeloma (MM)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted MM epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

Multiple Myeloma (MM) Understanding

According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65-74.

Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow. Treatment for multiple myeloma usually includes anti-myeloma medicines to destroy the myeloma cells or control cancer when it comes back (relapses) and medicines and procedures to prevent and treat problems caused by myeloma - such as bone pain, fractures, and anemia.

Epidemiology Perspective by DelveInsight

The MM epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The MM epidemiology data are studied through MM possible division to give a better understanding of the Disease scenario in the 8MM.

The disease epidemiology covered in the report provides historical as well as forecasted MM epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of MM, Total Incident Cases of MM Segmented by Gender, Total Incident Cases of MM Segmented by Age, Total Cases of MM by Line of Treatment] scenario of MM in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030.

MM Detailed Epidemiology Segmentation

  • In the year 2017, the total incident case of Multiple Myeloma was 85,971 cases in the 8MM. The United States, in 2017, accounted for 30,271 cases (the highest number), which will probably rise by the year 2030.
  • Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma was in Germany 7,337, in the year 2017. In the year 2017, the total incident cases of Multiple Myeloma was 7,504 in Japan. In the year 2017, the total incident cases of Multiple Myeloma was 19,536 in China, which might increase cases by 2030.
  • In China, the total incident cases of Multiple Myeloma was 19,536 in 2017.
  • In 2017, the 8MM total symptomatic cases of Multiple Myeloma was 75,679. In addition to this, the United States, in 2017, accounted for 26,647 cases.
  • In gender-specific cases of Multiple Myeloma, males are frequently affected by Multiple Myeloma (accounted for approximately 55% of cases) in comparison to females.
  • In age-specific cases of MM, in 2017, the most number of cases were seen in the age-group 65-74, followed by the age-group of 75-84 years, and 55-64 years.
  • In the 8MM, the total cases of Multiple Myeloma by treatment line were 22,124 cases for frontline transplant eligible patients, 46,676 cases for frontline transplant ineligible patients, 42,244 cases for second-line patients, 22,092 cases for third-line patients, and 9,629 cases for fourth-line plus patients, in the year 2017

Scope of the Report:

  • The MM report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
  • The MM Report and Model provide an overview of the risk factors and global trends of MM in the seven major markets (8MM: United States, Germany, France, Italy, Spain, and the United Kingdom, Japan, and China).
  • The report provides insight about the historical and forecasted patient pool of MM in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan and China, and China.
  • The report helps to recognize the growth opportunities in the 8MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of MM.
  • The report provides the segmentation of the MM epidemiology by total Incidence of MM in the 8MM.
  • The report provides the segmentation of the MM epidemiology by total symptomatic cases of Multiple Myeloma in the 8MM.
  • The report provides the segmentation of the MM epidemiology by Age and Gender in the 8MM.
  • The report provides the segmentation of the MM epidemiology by Line-wise Treated Patient Pool of MM in the 8MM.

Report Highlights:

  • 11-Year Forecast of MM epidemiology
  • 8MM Coverage
  • Total Incident Cases of Multiple Myeloma in the 8MM
  • Total Symptomatic Incident Cases of Multiple Myeloma in the 8MM
  • Incident Cases of MM according to segmentation: Age, and Gender
  • Treated cases of MM

KOL-Views

We interview, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over MM scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 8MM with respect to the patient population pertaining to MM ?
  • What are the key findings pertaining to the Multiple Myeloma epidemiology across the 8MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of Multiple Myeloma across the 8MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the 8MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?

Reasons to buy:

The MM Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global MM market
  • Quantify patient populations in the global MM market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MM therapeutics in each of the markets covered
  • Understand the magnitude of MM population by its severity
  • The MM epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The MM Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China

Study Period: 2017-2030

Total Incident cases of MM in the United States was assessed to be 30,271 in 2017, and are expected to decline during the study period. Among the European 5 countries, the highest number of incident cases of Multiple Myeloma were in Germany 7,337, in the year 2017

Table of Contents

1. Key Insights

2. Executive Summary of Multiple Myeloma (MM)

3. KOL Views

4. SWOT Analysis of Multiple Myeloma (MM)

5. Multiple Myeloma: Market Overview at a Glance

6. Disease Background and Overview: Multiple Myeloma (MM)

  • 6.1. Introduction
  • 6.2. Multiple Myeloma features
    • 6.2.1. Low blood counts
    • 6.2.2. Bone and calcium problems
    • 6.2.3. Infections
    • 6.2.4. Kidney problems
  • 6.3. Causes of Multiple Myeloma
  • 6.4. Risk factors of Multiple Myeloma
  • 6.5. Signs and Symptoms
    • 6.5.1. Bone Problems
    • 6.5.2. Low blood counts
    • 6.5.3. High blood levels of calcium
    • 6.5.4. Nervous system symptoms
    • 6.5.5. Kidney Problems
    • 6.5.6. Infections
  • 6.6. Pathogenesis of Multiple Myeloma
    • 6.6.1. Molecular mechanisms underlying the progression of multiple myeloma
    • 6.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
  • 6.7. Pathophysiology of Multiple Myeloma
  • 6.8. Patient-related risk factors
  • 6.9. Biomarkers for Multiple Myeloma
    • 6.9.1. Serum M-protein and light chains as biomarkers
    • 6.9.2. Potential proteomic biomarkers
    • 6.9.3. Cytogenetic biomarkers in multiple myeloma

7. Diagnosis of Multiple Myeloma

  • 7.1. Lab tests
  • 7.2. Biopsies
  • 7.3. Imaging tests
  • 7.4. Stages of Multiple Myeloma

8. Epidemiology and Patient Population

  • 8.1. Epidemiology Key Findings
  • 8.2. Assumptions and Rationale: 8MM
  • 8.3. Epidemiology Scenario: 8MM
    • 8.3.1. Total Incident Cases of Multiple Myeloma in the 8MM
    • 8.3.2. Total Symptomatic Cases of Multiple Myeloma in the 8MM
    • 8.3.3. Gender-specific cases of Multiple Myeloma in the 8MM
    • 8.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM
    • 8.3.5. Cases of Multiple Myeloma by Treatment Line in the 8MM

9. The United States Epidemiology

  • 9.1. Total Incident Cases of Multiple Myeloma in the United States
  • 9.2. Total Symptomatic Cases of Multiple Myeloma in the United States
  • 9.3. Gender-specific cases of Multiple Myeloma in the United States
  • 9.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United States
  • 9.5. Cases of Multiple Myeloma by Treatment Line in the United States

10. EU-5 Epidemiology

  • 10.1. Germany
    • 10.1.1. Total Incident Cases of Multiple Myeloma in Germany
    • 10.1.2. Total Symptomatic Cases of Multiple Myeloma in Germany
    • 10.1.3. Gender-specific cases of Multiple Myeloma in Germany
    • 10.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Germany
    • 10.1.5. Cases of Multiple Myeloma by Treatment Line in Germany
  • 10.2. France
    • 10.2.1. Total Incident Cases of Multiple Myeloma in France
    • 10.2.2. Total Symptomatic Cases of Multiple Myeloma in France
    • 10.2.3. Gender-specific cases of Multiple Myeloma in France
    • 10.2.4. Diagnosed cases of Multiple Myeloma by Age Distribution in France
    • 10.2.5. Cases of Multiple Myeloma by Treatment Line in France
  • 10.3. Italy
    • 10.3.1. Total Incident Cases of Multiple Myeloma in Italy
    • 10.3.2. Total Symptomatic Cases of Multiple Myeloma in Italy
    • 10.3.3. Gender-specific cases of Multiple Myeloma in Italy
    • 10.3.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Italy
    • 10.3.5. Cases of Multiple Myeloma by Treatment Line in Italy
  • 10.4. Spain
    • 10.4.1. Total Incident Cases of Multiple Myeloma in Spain
    • 10.4.2. Total Symptomatic Cases of Multiple Myeloma in Spain
    • 10.4.3. Gender-specific cases of Multiple Myeloma in Spain
    • 10.4.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Spain
    • 10.4.5. Cases of Multiple Myeloma by Treatment Line in Spain
  • 10.5. The United Kingdom
    • 10.5.1. Total Incident Cases of Multiple Myeloma in the United Kingdom
    • 10.5.2. Total Symptomatic Cases of Multiple Myeloma in the United Kingdom
    • 10.5.3. Gender-specific cases of Multiple Myeloma in the United Kingdom
    • 10.5.4. Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom
    • 10.5.5. Cases of Multiple Myeloma by Treatment Line in the United Kingdom

11. Japan Epidemiology

  • 11.1. Japan
    • 11.1.1. Total Incident Cases of Multiple Myeloma in Japan
    • 11.1.2. Total Symptomatic Cases of Multiple Myeloma in Japan
    • 11.1.3. Gender-specific cases of Multiple Myeloma in Japan
    • 11.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in Japan
    • 11.1.5. Cases of Multiple Myeloma by Treatment Line in Japan

12. China Epidemiology

  • 12.1. China
    • 12.1.1. Total Incident Cases of Multiple Myeloma in China
    • 12.1.2. Total Symptomatic Cases of Multiple Myeloma in China
    • 12.1.3. Gender-specific cases of Multiple Myeloma in China
    • 12.1.4. Diagnosed cases of Multiple Myeloma by Age Distribution in China
    • 12.1.5. Cases of Multiple Myeloma by Treatment Line in China

13. Appendix

  • 13.1. Bibliography
  • 13.2. Report Methodology

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

  • Table 1 Summary of MM Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Cytogenetic Abnormalities on Clinical Course and Prognosis in Multiple Myeloma
  • Table 3 The Revised International Staging System
  • Table 4 International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma and Related Plasma Cell Disorders
  • Table 5 Recommendations for the use of ¹?F-FDG PET/CT in patients with multiple myeloma and other plasma cell disorders
  • Table 6 Total Incident Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Table 7 Total Symptomatic Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Table 8 Gender-specific cases of Multiple Myeloma in the 8MM (2017-2030)
  • Table 9 Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017-2030)
  • Table 10 Cases of Multiple Myeloma by Treatment Line in the 8MM (2017-2030)
  • Table 11 Total Incident Cases of Multiple Myeloma in the United States (2017-2030)
  • Table 12 Total Symptomatic Cases of Multiple Myeloma in the United States (2017-2030)
  • Table 13 Gender-specific cases of Multiple Myeloma in the United States (2017-2030)
  • Table 14 Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017-2030)
  • Table 15 Cases of Multiple Myeloma by Treatment Line in the United States (2017-2030)
  • Table 16 Total Incident Cases of Multiple Myeloma in Germany (2017-2030)
  • Table 17 Total Symptomatic Cases of Multiple Myeloma in Germany (2017-2030)
  • Table 18 Gender-specific cases of Multiple Myeloma in Germany (2017-2030)
  • Table 19 Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017-2030)
  • Table 20 Cases of Multiple Myeloma by Treatment Line in Germany (2017-2030)
  • Table 21 Total Incident Cases of Multiple Myeloma in France (2017-2030)
  • Table 22 Total Symptomatic Cases of Multiple Myeloma in France (2017-2030)
  • Table 23 Gender-specific cases of Multiple Myeloma in France (2017-2030)
  • Table 24 Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017-2030)
  • Table 25 Cases of Multiple Myeloma by Treatment Line in France (2017-2030)
  • Table 26 Total Incident Cases of Multiple Myeloma in Italy (2017-2030)
  • Table 27 Total Symptomatic Cases of Multiple Myeloma in Italy (2017-2030)
  • Table 28 Gender-specific cases of Multiple Myeloma in Italy (2017-2030)
  • Table 29 Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017-2030)
  • Table 30 Cases of Multiple Myeloma by Treatment Line in Italy (2017-2030)
  • Table 31 Total Incident Cases of Multiple Myeloma in Spain (2017-2030)
  • Table 32 Total Symptomatic Cases of Multiple Myeloma in Spain (2017-2030)
  • Table 33 Gender-specific cases of Multiple Myeloma in Spain (2017-2030)
  • Table 34 Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017-2030)
  • Table 35 Cases of Multiple Myeloma by Treatment Line in Spain (2017-2030)
  • Table 36 Total Incident Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Table 37 Total Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Table 38 Gender-specific cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Table 39 Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017-2030)
  • Table 40 Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017-2030)
  • Table 41 Total Incident Cases of Multiple Myeloma in Japan (2017-2030)
  • Table 42 Total Symptomatic Cases of Multiple Myeloma in Japan (2017-2030)
  • Table 43 Gender-specific cases of Multiple Myeloma in Japan (2017-2030)
  • Table 44 Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017-2030)
  • Table 45 Cases of Multiple Myeloma by Treatment Line in Japan (2017-2030)
  • Table 46 Total Incident Cases of Multiple Myeloma in China (2017-2030)
  • Table 47 Total Symptomatic Cases of Multiple Myeloma in China (2017-2030)
  • Table 48 Gender-specific cases of Multiple Myeloma in China (2017-2030)
  • Table 49 Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017-2030)
  • Table 50 Cases of Multiple Myeloma by Treatment Line in China (2017-2030)

List of Figures

  • Figure 1 Multiple Myeloma (MM) SWOT Analysis
  • Figure 2 Interactions of MM tumor cells with the BM microenvironment. Five kinds of cells in the BM microenvironment are depicted, as well as a few of the complex interactions among these cells and MM cells.
  • Figure 3 Interaction of multiple myeloma cells in their bone marrow milieu
  • Figure 4 Technological advances in detecting biomarkers in multiple myeloma.
  • Figure 5 The National Comprehensive Cancer Network (NCCN) recommendations for initial diagnostic workup of patients with suspected MM
  • Figure 6 Global Heat Map of Multiple Myeloma
  • Figure 7 Total Incident Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Figure 8 Symptomatic Cases of Multiple Myeloma in the 8MM (2017-2030)
  • Figure 9 Gender-specific cases of Multiple Myeloma in the 8MM (2017-2030)
  • Figure 10 Diagnosed cases of Multiple Myeloma by Age Distribution in the 8MM (2017-2030)
  • Figure 11 Cases of Multiple Myeloma by Treatment Line in the 8MM (2017-2030)
  • Figure 12 Total Incident Cases of Multiple Myeloma in the United States (2017-2030)
  • Figure 13 Symptomatic Cases of Multiple Myeloma in the United States (2017-2030)
  • Figure 14 Gender-specific cases of Multiple Myeloma in the United States (2017-2030)
  • Figure 15 Diagnosed cases of Multiple Myeloma by Age Distribution in the United States (2017-2030)
  • Figure 16 Cases of Multiple Myeloma by Treatment Line in the United States (2017-2030)
  • Figure 17 Total Incident Cases of Multiple Myeloma in Germany (2017-2030)
  • Figure 18 Symptomatic Cases of Multiple Myeloma in Germany (2017-2030)
  • Figure 19 Gender-specific cases of Multiple Myeloma in Germany (2017-2030)
  • Figure 20 Diagnosed cases of Multiple Myeloma by Age Distribution in Germany (2017-2030)
  • Figure 21 Cases of Multiple Myeloma by Treatment Line in Germany (2017-2030)
  • Figure 22 Total Incident Cases of Multiple Myeloma in France (2017-2030)
  • Figure 23 Symptomatic Cases of Multiple Myeloma in France (2017-2030)
  • Figure 24 Gender-specific cases of Multiple Myeloma in France (2017-2030)
  • Figure 25 Diagnosed cases of Multiple Myeloma by Age Distribution in France (2017-2030)
  • Figure 26 Cases of Multiple Myeloma by Treatment Line in France (2017-2030)
  • Figure 27 Total Incident Cases of Multiple Myeloma in Italy (2017-2030)
  • Figure 28 Symptomatic Cases of Multiple Myeloma in Italy (2017-2030)
  • Figure 29 Gender-specific cases of Multiple Myeloma in Italy (2017-2030)
  • Figure 30 Diagnosed cases of Multiple Myeloma by Age Distribution in Italy (2017-2030)
  • Figure 31 Cases of Multiple Myeloma by Treatment Line in Italy (2017-2030)
  • Figure 32 Total Incident Cases of Multiple Myeloma in Spain (2017-2030)
  • Figure 33 Symptomatic Cases of Multiple Myeloma in Spain (2017-2030)
  • Figure 34 Gender-specific cases of Multiple Myeloma in Spain (2017-2030)
  • Figure 35 Diagnosed cases of Multiple Myeloma by Age Distribution in Spain (2017-2030)
  • Figure 36 Cases of Multiple Myeloma by Treatment Line in Spain (2017-2030)
  • Figure 37 Total Incident Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Figure 38 Symptomatic Cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Figure 39 Gender-specific cases of Multiple Myeloma in the United Kingdom (2017-2030)
  • Figure 40 Diagnosed cases of Multiple Myeloma by Age Distribution in the United Kingdom (2017-2030)
  • Figure 41 Cases of Multiple Myeloma by Treatment Line in the United Kingdom (2017-2030)
  • Figure 42 Total Incident Cases of Multiple Myeloma in Japan (2017-2030)
  • Figure 43 Symptomatic Cases of Multiple Myeloma in Japan (2017-2030)
  • Figure 44 Gender-specific cases of Multiple Myeloma in Japan (2017-2030)
  • Figure 45 Diagnosed cases of Multiple Myeloma by Age Distribution in Japan (2017-2030)
  • Figure 46 Cases of Multiple Myeloma by Treatment Line in Japan (2017-2030)
  • Figure 47 Total Incident Cases of Multiple Myeloma in China (2017-2030)
  • Figure 48 Symptomatic Cases of Multiple Myeloma in China (2017-2030)
  • Figure 49 Gender-specific cases of Multiple Myeloma in China (2017-2030)
  • Figure 50 Diagnosed cases of Multiple Myeloma by Age Distribution in China (2017-2030)
  • Figure 51 Cases of Multiple Myeloma by Treatment Line in China (2017-2030)